Checkpoint Inhibitor Refractory Cancer Market Poised for Growth as Novel Immuno-Oncology Candidates Target Resistance
核心洞察
The checkpoint inhibitor refractory cancer market is expected to grow significantly by 2036, driven by rising resistance to immune checkpoint inhibitors and demand for next-generation therapies.
Approximately 40–60% of patients with melanoma (搜索), NSCLC, renal cell carcinoma (搜索), urothelial carcinoma (搜索), and head and neck cancers experience primary resistance to PD-1 (搜索)/PD-L1 (搜索) inhibitor therapy.
Promising investigational therapies include Sitravatinib + Nivolumab, TAVO + Pembrolizumab, Botensilimab + Balstilimab, and ICT01, which aim to overcome resistance and restore antitumor immunity.
The checkpoint inhibitor refractory cancer market is anticipated to witness significant growth and evolution through 2036, driven by the widespread adoption of immune checkpoint inhibitors, increasing awareness of resistance mechanisms, and the pressing need for next-generation therapeutic approaches capable of overcoming resistance and restoring effective antitumor immunity in patients refractory to existing immunotherapies.
In many cancers such as melanoma (搜索), non-small cell lung cancer (搜索) (NSCLC), renal cell carcinoma (搜索), urothelial carcinoma (搜索), and head and neck cancers, approximately 40–60% of patients experience primary resistance to PD-1 (搜索)/PD-L1 (搜索) inhibitor therapy, while a substantial proportion of initial responders eventually develop acquired resistance and disease progression. This growing unmet clinical need is driving demand for novel therapies specifically designed to overcome refractory disease.
Emerging Therapies Targeting Immune Resistance
Leading checkpoint inhibitor refractory cancer companies, including Mirati Therapeutics (搜索), Bristol Myers Squibb (搜索), OncoSec Medical (搜索), Agenus, Compass Therapeutics, TILT Biotherapeutics (搜索), ImCheck Therapeutics, Phanes Therapeutics (搜索), OncoC4 (搜索), CanBas Co. Ltd., and Sumitomo Pharma America, Inc., are developing new treatment drugs expected to reach the market in the coming years.
Sitravatinib is an orally administered, spectrum-selective tyrosine kinase inhibitor that targets the TAM receptor family (TYRO3 (搜索), AXL (搜索), and MERTK (搜索)), along with VEGFR (搜索) and MET signaling pathways. It is designed to remodel the immunosuppressive tumor microenvironment and restore responsiveness to immune checkpoint inhibitors. In combination with nivolumab, sitravatinib is being evaluated for advanced solid tumors that have progressed despite prior checkpoint inhibitor therapy, with a primary focus on NSCLC and renal cell carcinoma (搜索) (RCC). Updated Phase II results presented in April 2025 demonstrated continued clinical activity of sitravatinib plus nivolumab in patients with metastatic clear-cell RCC who had experienced disease progression following previous immune checkpoint inhibitor treatment.
OncoSec Medical (搜索)'s Tavokinogene telseplasmid (TAVO) is an investigational intratumoral IL-12 plasmid immunotherapy administered through electroporation to induce localized cytokine expression and strengthen antitumor immune responses. Combined with pembrolizumab, TAVO aims to transform immunologically "cold" tumors into "hot" tumors, improving their responsiveness to PD-1 (搜索) inhibition. The FDA has granted TAVO Fast Track designation for metastatic melanoma (搜索) that has progressed after prior anti-PD-1 therapy.
ImCheck Therapeutics' ICT01 is a humanized monoclonal antibody targeting BTN3A (搜索) (CD277) that selectively activates γ9δ2 T cells, key immune cells involved in the surveillance and elimination of malignant and infected cells. The three BTN3A isoforms recognized by ICT01 are highly expressed across a broad range of solid tumors, including melanoma (搜索), urothelial, colorectal, ovarian, pancreatic, and lung cancers, as well as hematologic malignancies such as leukemia and lymphoma. In July 2025, ICT01 received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (搜索) (AML).
Botensilimab Plus Balstilimab Shows Promise
Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that the Botensilimab plus balstilimab combination may achieve particularly strong uptake if ongoing registrational studies continue to demonstrate meaningful survival benefits in microsatellite-stable colorectal cancer (搜索) and other immunotherapy-resistant tumors.
Recent clinical developments underscore this potential. In May 2026, Agenus presented Phase II data for botensilimab plus balstilimab (BOT+BAL) in advanced cutaneous melanoma (搜索) refractory or resistant to prior anti–PD-(L)1 therapy, including patients previously exposed to CTLA-4 (搜索) inhibitors. The findings, presented at the ASCO Annual Meeting 2026, highlighted continued clinical activity in a heavily pretreated population with limited treatment options.
In April 2026, Agenus reported positive Phase II data evaluating botensilimab and balstilimab in combination with agenT-797 in patients with PD-1 (搜索)-refractory gastroesophageal adenocarcinoma (搜索). The study demonstrated a disease control rate of 77% and durable survival outcomes in heavily pretreated patients.
Current Treatment Landscape and Unmet Need
Management of checkpoint inhibitor-refractory cancer is centered on overcoming mechanisms of immune resistance, reactivating antitumor immunity, delaying disease progression, extending survival, and enhancing patients' quality of life. Existing treatment approaches differ across tumor types and may involve alternative immune checkpoint inhibitor combinations, targeted therapies, chemotherapy, radiotherapy, tumor-infiltrating lymphocyte (TIL) therapy, or participation in clinical trials evaluating novel immuno-oncology agents.
Recent therapeutic advances, including the approval of Lifileucel (AMTAGVI), have highlighted the promise of adoptive cell therapy for patients with advanced melanoma (搜索) whose disease progresses following checkpoint inhibitor therapy. Similarly, targeted therapies such as Erdafitinib (BALVERSA), along with combination immunotherapy regimens, are increasingly being used in selected patients based on molecular and genomic characteristics.
Nevertheless, effective treatment options remain limited for many individuals with primary or acquired resistance to immune checkpoint inhibitors, and durable long-term responses continue to be a significant unmet need. The therapeutic landscape is increasingly shifting toward next-generation immunotherapies and innovative strategies designed to overcome immune resistance, including Botensilimab + Balstilimab, Domvanalimab + Zimberelimab, Sitravatinib + Nivolumab, Bemcentinib + Pembrolizumab, Visugromab (CTL-002), CUE-101, CMP-001 + Nivolumab, and TAVO + Pembrolizumab.
Market Outlook
The total checkpoint inhibitor refractory cancer treatment market size is expected to grow positively by 2036 in the leading markets, which include the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The United States accounted for the largest checkpoint inhibitor refractory cancer treatment market size in the 7MM in 2025, compared to other major markets, driven by high immunotherapy utilization rates, broad access to innovative oncology treatments, and a large cancer patient population.
As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the checkpoint inhibitor refractory cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.